braininnovationdays2020square

Brain Innovation days 2020 – Save the date!

SAVE THE DATE ! European Brain Council and beLean.net launch the first Brain Innovation Days, which will take place on 13-14 October 2020 physically in Brussels and virtually all over Europe. October 2020 13-14 Brussels, Belgium Add to calendar: GOOGLE APPLE ICAL OUTLOOK OUTLOOK.COM 179 million Europeans are currently living with brain disorders, and this is to steadily increase as[…]

pdcline_bfmbusiness

PDC*line Pharma on BMF Business

Eric Halioua, President & CEO of PDC*line Pharma, was invited on BMF Business to speak about the new class of immunotherapies active against cancer which his team is developing. Watch the replay here: Contact us to get more information: Source: https://bfmbusiness.bfmtv.com/mediaplayer/video/eric-halioua-pdcline-pharma-pdcline-pharma-developpe-une-nouvelle-classe-d-immunotherapies-actives-contre-les-cancers-0205-1244108.html  

favicon_20200415_Press-Release-COVID19-Vaccine

Univercells announces fast-track development of a COVID-19 vaccine with ReiThera and Leukocare

ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine. Italian ReiThera Srl. (Rome), German LEUKOCARE AG (Munich), and Belgian Univercells S.A. (Brussels), today announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19. The vaccine candidate is expected to enter[…]

conference-room-768441_1280

COVID-19: Comment organiser son assemblée générale en cette période de distanciation sociale ?

Le Vice-Premier ministre et ministre de la Justice Koen Geens l’avait annoncé dans un communiqué de presse, l’arrêté royal n°4 qui permet aux sociétés d’organiser de manière flexible leurs assemblées générales malgré les mesure de confinement a été publié au Moniteur belge le 9 avril 2020. Toute société ou association qui n’aurait pas explicitement précisé[…]

belean_coronavirus_guide_startup

COVID-19: Guide de survie des start-ups

Cliquez ici pour télécharger gratuitement notre guide de survie des start-ups face à la crise du COVID-19. Les nouvelles et le stress associés au COVID-19 dans le monde entier créent le doute, l’incertitude et l’anxiété parmi les dirigeants, les employés et les clients. Au-delà des mesures de bon sens prises par le gouvernement, nous voulons, chez beLean.net,[…]

savics_coronavirus_datatocare

Savics’ DataToCare software will be used to collect, gather and analyze COVID-19 test results

Savics is collaborating since more than 2 weeks with KU Leuven and DNAlytics to collect, gather and analyze COVID-19 test results. DataToCare COVID-19 is/will be used by all 7 University Laboratories across Belgium that support and unload the Belgian COVID-19 Reference Laboratory from UZ Leuven. DataToCare COVID-19 is a software installed in laboratories that capture COVID-19 test results and[…]

univercells_coronavirus_bultot

Univercells in the race for the coronavirus vaccine

With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot. Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 15,000-square-meter[…]

pdcLine-Pharma-dendritic-cell-cancer-vaccine

PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate targeting non-small cell lung cancer

Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]

univercells_press_release

Univercells secures up to €50M investment from KKR platform

BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]

OncoDNA-cancer-diagnostics

OncoDNA Closes Successful Series B Investment Round

GOSSELIES, BELGIUM – FEBRUARY 14TH, 2020 — OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives. The round was led by Vesalius Biocapital[…]

MaSTherCell_250x250

MaSTherCell is acquired by Catalent for $315 Million

GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]

pdc_biotech_finances

PDC*line Pharma’s recent fund raising is described in the latest issue of Biotech Finances

Check the latest issue of Biotech Finances to read an interview of PDC*line Pharma’s President & CEO Eric Halioua describing the recent fund raising completed and the perspectives of the company.   Read the full article: https://www.biotech-finances.com/126504-2/ Contact us to get more information:

blqDNtyA

Our client PDC*line Pharma raises $22.2M in series B financing round

Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]

BioWin_gdv

We gave a lecture about clinical trials funding at “Anchoring Clinical Research in Belgium”

We took part in the event “Anchoring Clinical Research in Belgium” jointly organized by BioWin and flanders.bio in Brussels where we had an interesting debate on funding opportunities for biomedical research and clinical trials development in a sector where Belgium is leading globally. Thank you to Bone Therapeutics, icometrix and Ayming Belgium for sharing the stage.              […]